Early identification of ARIA through MRI is essential for the safe administration of anti-amyloid monoclonal antibodies. While many ARIA cases are asymptomatic, radiological findings can precede severe neurological complications, highlighting the need for ongoing radiological surveillance. This poster provides radiologists with some critical insights for identifying and monitoring ARIA, to optimize patient care and prevent adverse clinical outcomes. As of February 2025, anti-amyloid β monoclonal antibodies are not yet approved for routine clinical use in Europe and are administered exclusively within clinical trials. However, the European Medicines Agency has recently recommended granting marketing authorisation for Lecanemab. This development suggests that approval for general clinical use may be forthcoming, necessitating preparation by healthcare professionals involved in Alzheimer's care.